What are the AHA/ASA guidelines for antithrombotic therapy in dilated cardiomyopathy-related transient ischemic attack (TIA)?

Updated: Dec 03, 2018
  • Author: Ashish Nanda, MD; Chief Editor: Andrew K Chang, MD, MS  more...
  • Print

In dilated cardiomyopathy, either oral anticoagulation with warfarin (target INR, 2-3) or antiplatelet therapy may be considered. In rheumatic mitral valve disease, oral anticoagulation with warfarin (target INR, 2-3) is reasonable. Antiplatelet agents would not normally be added to warfarin unless patients experience recurrent embolism despite a therapeutic INR. The benefit of warfarin after stroke or TIA in patients with sinus rhythm and cardiomyopathy characterized by systolic dysfunction has not been established. [46]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!